Blog
RSS FeedPosted by Michael Wonder on 30 Mar 2022
Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm
30 March 2022 - Tagraxofusp is human interleukin-3 genetically conjugated to diphtheria toxin protein. ...
Posted by Michael Wonder on 28 Mar 2022
Atidarsagene autotemcel for treating metachromatic leukodystrophy
28 March 2022 - NICE has published evidence-based recommendations on atidarsagene autotemcel (Libmeldy) for treating metachromatic leukodystrophy in children. ...
Posted by Michael Wonder on 24 Mar 2022
Priorities for NICE in health and social care
23 March 2022 - Over the past two years there has been an unprecedented increase in medical research, the NHS has ...
Posted by Michael Wonder on 24 Mar 2022
Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
24 March 2022 - NICE has published evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated advanced renal cell ...
Posted by Michael Wonder on 23 Mar 2022
Acceptability of manufacturer proposed utility values for NICE cancer medicine appraisals: analysis of manufacturers’ information sources
21 March 2022 - The NICE method guide for technology appraisals encourages medicine manufacturers to use the EuroQol 5 Dimension in ...
Posted by Michael Wonder on 21 Mar 2022
NICE recommends elosulfase alfa for routine NHS use for patients with rare life-limiting metabolic disorder
21 March 2022 - NICE has today published final draft guidance recommending elosulfase alfa (Vimizim; BioMarin) for routine use in ...
Posted by Michael Wonder on 20 Mar 2022
NHS fast tracks new ‘gamechanging’ drug for lung cancer
18 March 2022 - A targeted new drug for a rare and aggressive form of lung cancer will be fast-tracked ...
Posted by Michael Wonder on 18 Mar 2022
Update to the statutory scheme to control the costs of branded health service medicines
15 March 2022 - The UK Government is seeking views on its proposal to increase the rate of payments made ...
Posted by Michael Wonder on 16 Mar 2022
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
16 March 2022 - NICE has published evidence-based recommendations on the use of dostarlimab (Jemperli) for the treatment of adults ...
Posted by Michael Wonder on 16 Mar 2022
Life-extending injection for blood cancer available on the NHS
15 March 2022 - A life-extending injection for a fatal form of blood cancer will be available to around 350 ...
Posted by Michael Wonder on 14 Mar 2022
Teduglutide for treating short bowel syndrome
11 March 2022 - The Department of Health and Social Care has asked NICE to produce guidance on using teduglutide ...
Posted by Michael Wonder on 14 Mar 2022
Imlifidase for preventing kidney transplant rejection in people with chronic kidney disease
11 March 2022 - The Department of Health and Social Care has asked NICE to produce guidance on using imlifidase ...
Posted by Michael Wonder on 10 Mar 2022
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea
9 March 2022 - NICE has published evidence based recommendations on the use of solriamfetol hydrochloride (Sunosi) for the treatment ...
Posted by Michael Wonder on 10 Mar 2022
Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea
9 March 2022 - NICE has published evidence based recommendations on the use of pitolisant hydrochloride for the treatment of ...
Posted by Michael Wonder on 10 Mar 2022
Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria
9 March 2022 - NICE has published evidence based recommendations on the use of pegcetacoplan (Aspaveli) for the treatment of ...